SCHEMBL20652968

SCHEMBL20652968

CC(C)n1c(=O)[nH]c(=O)c2[nH]c(-c3cccnc3Cl)nc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 1/20 0.53
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GLA P06280 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ CASP7 P55210 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ADORA2A P29274 1/20 0.37
▸ ADORA2B P29275 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MET P08581 2/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PTGES O14684 1/20 0.34
▸ PDE5A O76074 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20652982 0.82 KMT2A (0.36) ADORA1KMT2AKDM4EALDH1A1GLA
SCHEMBL20655914 0.82 KDM4E (0.47) ADORA1KMT2AKDM4EALDH1A1GLA
SCHEMBL20652782 0.82 ADORA2A (0.34) ADORA1KMT2AKDM4EALDH1A1GLA
SCHEMBL20652749 0.78 KDM4E (0.41) ADORA1KMT2AKDM4EALDH1A1GLA
SCHEMBL22105441 0.78 ALDH1A1 (0.36) KMT2AKDM4EALDH1A1GLACASP1
SCHEMBL20652780 0.74 KMT2A (0.37) KMT2AKDM4EALDH1A1GLACASP1
SCHEMBL22109857 0.72 MTOR (0.34) KMT2AKDM4EALDH1A1GLACASP1
SCHEMBL2333182 0.68 ADORA2B (0.61) ADORA1ADORA2AADORA2B
SCHEMBL2243952 0.67 DAO (0.58) ALDH1A1MTORPDE5A
SCHEMBL29910188 0.67 ADORA1 (0.60) ADORA1KMT2AKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 ADORA1 439/4885KMT2A 4180/4885KDM4E 3884/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 ADORA1 436/4885KMT2A 4155/4885KDM4E 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback